Consulting

Miraca can help your practice on the Journey to 2024. Navigate the changing healthcare landscape with confidence, through the complexities of Meaningful Use, PQRS, Value-based Modifier, Clinical Performance Improvement (CPI) other quality reporting programs, and soon, the Merit-based Incentive Payment System MIPS.

Through years of experience and hundreds of practices helped, Miraca’s consultants have developed significant expertise in the health IT initiatives that affect our clients. Our technical team is here to help your practice succeed, despite the many regulatory challenges.

  • Merit-based Incentive Payment System (MIPS) — Let Miraca help your practice prepare for the next step in the nationwide rollout of the pay-for-performance model.
    • PQRS Reporting — Understand which measures to report, options for reporting and how to seamlessly embed quality data reporting into your practice.
    • Value-based Modifier (VBM) — Get help with avoiding penalties, analyzing your new QRUR report, even participating without an EMR as the industry goes to a pay-for-performance model.
    • Meaningful Use Consulting — Navigate the requirements to attest and be ready for audits.
    • Clinical Practice Improvement Activities (CPIA) — We help you choose and implement new activities that earn points toward your MIPS score.
  • Quality Payment Program — This unified framework from CMS provides a new approach to paying clinicians—either MIPS or the Advanced Alternative Payment Models (APMs). Miraca helps you choose and implement the way forward for your practice.
  • HIPAA — HIPAA compliance is mandatory. Miraca can help you meet the requirements of the Security Rule and Privacy Rule, both of which keep patient’s electronic personal health information safe, private, and secure.
  • Security Assessments — A requirement of both HIPAA and Meaningful Use, Miraca can perform your annual Security Risk Assessment, which involves reviewing your practice’s physical, technical, and administrative policies and procedures that are currently in place. Uncovering risks is the first priority, mitigating them comes next.

Through each of these complex health IT initiatives, we want your practice to triumph!

Our expert technical consultants have a wealth of experience:

  • 2,500+ MU attestations submitted
  • 1,000+ MU audits completed with 97% success rate; 100% success rate in 2015!
  • 500+ security risk analyses performed
  • Regional Extension Center experience
  • Authors, trainers, coaches
  • Meet author Joy Rios, one of our distinguished consultants.

Contact Miraca Life Sciences to learn how Miraca can assist your practice.
Call 1.855.347.7284 or email HealthITConsulting@MiracaLS.com

The Miraca interface to EMA Dermatology is a powerful tool for accurate and thorough follow-up and tracking of biopsy results.
— Josephine Chu McAllister, MD,
Dermatologist/Founder, Dermatology Associates of Ithaca, Ithaca, N.Y.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


May 23, 2017

Miraca Life Sciences Again Expands Therapeutic Drug Monitoring with Addition of First Biosimilar Inflectra®

IRVING, Texas, May 23, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, has further expanded its InformTx™ therapeutic drug monitoring (TDM) capabilities with the addition of testing for Inflectra® (infliximab-dyyb), which is the first biosimilar drug in the test offering. Since launching InformTx in June 2016, Miraca Life Sciences has expanded the service from four to […]

Continue reading


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading